Right. Welcome, everyone, to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my pleasure to have the next fireside chat with ImmunityBio CEO, Rich Adcock. Welcome, Rich.
Thank you. First of all, I'd just like to say thank you to the Jefferies team for inviting us and for everybody here being present in the audience.
Excellent. All right. Richard, why not you give us some overview of ImmunityBio, where you're coming from, what you're heading to, and why you're excited about the future, and particularly 2027, then we do have a lot of the specifics we can talk about today.
Sounds great. I think maybe one of the things to just, let's just jump right into is Q3, as we look at what's happening there on those. Before I start on any of those, I'll just start almost just exactly like the last one. We're not going to be providing any forward guidance for 2027 or what's happening in the current quarter on those pieces. Refer for everybody over to 10-Qs and 10-Ks for all of those pieces. But our Q3, we saw a nearly $49 million quarter, about a 53% growth year-over-year, slightly down over the prior quarter on those pieces, but about almost $144 million in sales for the first nine months of the year. So we're really happy with that. But I think the bigger part of what happened in Q3 was really about the expansion.
Because our first label that we have is the smallest part of bladder cancer, CIS plus or minus, and end of October, plus or minus, is when we actually received, and we are the first in the world to actually receive this, or first in the U.S. to receive this. We now have the entire BCG-unresponsive, so CIS plus and minus papillary alone. That is really a very important piece because if you look at that, it is somewhere between two to three or 4x larger market, but more important than what the market size is what it does for the doctors.
I will tell you, the day that we got that approval, and probably over the couple of days that we got that approval, I probably had, I do not know, 20 physicians that would just call me personally, say, "Congratulations." They almost all said the same thing, "Finally, I can get back to treating my patients the way I see them. I have high-risk patients that are either BCG-naïve, or I have high-risk patients that are BCG-unresponsive. This nonsense about this CIS plus and minus, it just makes our billing office and our life miserable through those." They would usually go on to say, "NCCN is cool, but it does not actually address what payers really want is they want the FDA approval, so congratulations, and you have made our life a lot easier now."
So we are really excited about that and happy to say that actually it is the second country that we got that in because the Emirates had previously approved it just prior to that with the full responsiveness on those. Beyond that, what is happening now and what happened in the last quarter as well was that we finished and met the endpoint that we reported out for our BCG-naïve. So in high risk, you have got the unresponsive space, and you have got the BCG-naïve. Kind of think of them as frontline, second line, if you make it simple.
Having met the endpoint for the BCG-naïve trial means, and we have been working on this in parallel because you do not write one of these in a day, there are 700,000 or 800,000 pages, we will submit our sBLA for BCG-naïve yet this year. So the team has really been going deep on that one, and we can go further into that in a little bit. I think those are some of the things I would kind of start to talk about and focus everybody in on.
Yeah, totally. Thanks, Rich. Maybe just on the 3Q earning, I believe, obviously, it's a very good number for nine months, year-on-year growth.
Yeah.
Then as you start to launch ANKTIVA. But that's the first time a quarterly drawdown. So what's the reason, and how concerned people should be, right? So maybe any comments you have there?
Thank you. The way I would look at it is, as we've always said on this one here is, and it's really important to put things in context, the CIS plus or minus piece is a very small market. And there's a certain point when you're going to kind of run up against the headroom of that one. And what we've always said is we have to get out of the CIS-only market, and we got to get into that full BCG- unresponsive market. So it was fortuitous that they gave it to us three months early, some would argue 10 months later than what we wanted it, because we wanted it prior on those pieces. But it's really important because that now gives us even more room to continue to grow inside of those.
Obviously, you've got more people in there, you've got competition in there, you've got BCG that we're working through, and we can talk a little bit about that.
Yep.
But I think that's the way of looking at it, is that the positive news of all of those pieces is that the market just got bigger for us, and right now we're alone in that pack.
Excellent. That's literally my next question—
Yeah.
—in terms of the papillary-only population. You just got approval in October, which is earlier than supposed to, the PDUFA day. Then what have you been seeing from that population in Q3, and then not in Q3, but in the Q4—
Yeah.
—then how you think about the growth driving into next year?
Yeah. It is really probably one of the most important pieces for us, and I say that more from even in 2026 from 2027. We got it, let's just say, at the end of October to make it simple. I will tell you that we are already seeing sales from that one right in there, but it always takes a little bit of time when they get those because doctors got to work through their processes and all of those to be able to get it online. We will see initial sales happening in Q4 through those, but the bigger piece of those we are expecting in 2027 because, again, we are the only one standing alone with that piece. We are also in that space, then submitting right now in for the BCG-naïve setting on that one.
I share that because when I am working with physicians, and I have personally traveled with and met with hundreds or more physicians, practices, I am always somebody who wants to be right out there and not hearing it filtered. I want to hear it right from a physician's mouth themselves. What they have told us is seeing that clear pipeline and clear path allows them when they are working through their algorithms is, "Which one do I pick next? How do I work through that one?" So getting that papillary-only really gave them the confidence, because there was many that did not think we were going to get it. We just smiled and said, "We are going to get it. We are just not done."
Because we had brought it forward the first time, and they said, "Well, we need more data." It was not more clinical data they needed. We needed to help them provide better context about what this immunotherapy really is doing in that space. I am very proud of the team for getting that done early.
Got it. Then, I know you are not giving us the guidance for next year yet, but you have been grow $7 million, $8 million a quarter. So with the papillary, before yo, w e can talk about the BCG-naïve population for sure, but before you have the BCG-naïve label or sales, how you think about this growth going to back to on track on the initial, the run rate, or maybe even higher because the population is a little bit higher for the CIS?
Too soon to tell. I mean, because we're just literally in the kind of the first single-digit days of having all of those pieces. That's what we'll be working on and providing more of that on those pieces.
Okay. You are the only one have the label for papillary. We know your competitor also got invited to submit the data. I think, I don't know about the data package because none of you have I think you have the data from the single arm trial. But the NCCN listing, they have that. How the difference between the FDA label vs NCCN listing, and then how the payer going to look at these two trial?
The last part you said I think is the most important is that obviously you need NCCN, but that alone is not enough, especially in this space because the urologists don't want to take the risk. We had that, and we would talk with urologists that are absolutely tier- 1, they love us, they love the drug, and they would say, "I'm not going to take the risk because it's not worth the cash flow if I get burned." We've seen too many practices get burned on these types of pieces, get the approval so we can see those, and that's what I was excited to see was on the approval.
They literally said, "Okay, now I got a patient, and let's start through the process on all of these pieces." I think that's what's really most important is you've got to have both, yes, they reported that they said they got invited through those. What I can tell you on ours is it wasn't just saying that, "Okay, it's all the same." We had to demonstrate to them that the patient population as it related to our mechanism of action, specifically in an immunotherapy approach, how it worked in there. I know right away people always say, "Oh, they'll just copy and paste." Well, it's a different mechanism of action. Ours is not a chemo, ours is an immunotherapy. I don't know what they're going to do on those pieces.
I know what we submitted, and I know the incredibly detailed scientific work that we had to bring forward, and that's what we have said on. If I had a chemo, I don't know how I would position it that way, but that'll be on them.
Yeah. It's their, the burden is on them to demonstrate—
That's right.
—if it's approvable or the benefit. Then, you say you already have the sales from the papillary-only. Then, how about the payer side? You already got the coverage, and then you get reimbursement from them?
It goes back to the last question you asked, because when you have both FDA approval and NCCN—
Yep.
—immediately CMS is covered. That is one of the benefits you get right there is you do not even have to go ask them. It just immediately kicks in, and you get all of that. That opens up hundreds of millions of people right away. But everybody else is following because we had already been presenting to them prior to our approval, "Here is what we are trying to bring forward for approval." The payers were very open about this. I have personally met with many of the large payers, and the thing that I hear, that I have personally heard from them, is that what they appreciate about ANKTIVA is the long duration of response. I ran a large billion-dollar-plus health plan, and I would always say, "I did not mind paying for expensive drugs.
I hated paying for expensive drugs that did not last." Because you put the money in, you do not get a return on those pieces. With ANKTIVA, and that is why we have even Kaiser is one of the people we have on those, and everybody knows Kaiser does amazing clinical care, but they always want to be, they are very cost-conscious, and they are looking for those trade-offs if they can work through those. I know that because I personally sat in the meetings with Kaiser. They were fantastic. Their health economists, when we were working through those, they keyed in on, "Of course you got a response. How long is the duration? What are you seeing? How long is that?" That is what matters to them, and others as well, as we have met with the Blues. So we are seeing that quick uptick on those.
In the smaller label, we said we had 240+ million lives covered. It will rapidly fill in on that one. That is why I say Q4 we will see impact on it, but it is really going to be 2027 that we will start to see more is what I am expecting. But again, we are just kind of single-digit days into this right now.
Is that like a six-month process, you can get a broader, as broad as a CIS-only, or CIS plus/minus papillary type of the coverage?
Yeah. I think as we look at those, that's what we'll be seeing right now. There's, on the payer side, that's going really well. The team under Matt Hilman, who lead our market access for the U.S., have done just a remarkable job on trying to bring those forward and be very creative and meet the payers where they are, because you can't say, "Here's my payer package," just drop them an email, because every payer has a different set of needs that they're looking at. Some want to look at it a value base, some want to look at it on this basis. What I can tell you is that we've had great response because we've met with all of them. They like the drug, they know the drug. Now they say we get to do it on a bigger basis.
Actually, for them, that benefits them because now they got a broader patient population they can impact.
Yeah. Got it. Another piece is, yes, you have to approve the drug now. You have a couple maybe down the pipeline and then maybe in the near term. So how do you think about the physician feedback, the use experience? You are already on the market and setting pretty good number. So how do you think about ANKTIVA usage versus all the practice and logistics compared to chemo and then some of the other immunotherapy?
I think that is really a differentiator. Obviously, I always emphasize duration, duration. ANKTIVA is the only, first, it is a chemo-free. Second, it is the only of every drug that is either on trial or approved that is administered by the nurse or the MA or the nurse practitioner. It is the exact same workflow as BCG, which has been used and is the standard of care for four decades. Literally, and it is my joke, maybe not a good one, I call it shaken, not stirred, because they know how to do BCG. You are literally adding ANKTIVA. It is the same syringe, the same catheter, the same hold time. It is the same EMR schedule. They do not change anything. From the ability to deploy, it is very, very, very easy.
Our medical affairs team come out, they do in-service trainings with them, and as I have said, I have been to many practices. I always, whenever I go out to a practice, make a point of this, and I have been doing this a long time, to spend time with the nurses. Both the nurses that are helping to manage the physician schedules, but also the BCG nurse, because he or she, as we will go through those, are the ones who really do it. Because inevitably, and I have seen this everywhere, they got this little drawer they pull out and there is a notebook, and that is the BCG patients. They know every one of those patients right there, and they know them by name, and because they have long-term relationships with these patients because they are going through them over the course of treatment.
Dr. Murray from NYU was talking, she says, "You know, when you get this, you and I are going to have a long-term relationship, but it is going to be a good one because we are going to get you through this process." That is one that hit me early on as she was talking about that, and you see that happening. By not changing the workflow and allowing the nurse to be able to do this allows the physician under the supervision, the nurse under the supervision of the physician, to be able to continue to do something else, and so their practice is growing. That is something that is really important because everybody knows surgeons, physicians, and healthcare is under a lot of pressure.
Giving them something that matches their exact in-place workflow, but literally the only thing they have to do is order two drugs instead of one, and then do the admixture. It is pretty straightforward, and that is a real benefit that we have and that others do not and won't.
Yeah. Okay, good. One of the things people keep talking, maybe you will address that very soon, is the BCG supply, because you rely on the combination with its BCG, which is a great drug, but the shortage supply seems to last a bit longer than people expected. You are addressing that, not just relying on other third party, you are addressing that by yourself. So tell us what is the status of that and how confident you are you can address that by the end of 2027?
Yeah. I always say in this one, I would love Merck to be able to solve it. They keep saying they are going to. I welcome them to do that. It would be wonderful. But we have not taken that approach, and the reason is that BCG is a couple hundred dollars, right? When they get their choice between something that is a blockbuster vs this, of course, it is playing out the way it is. ImmunityBio did two things in pretty short order. Right after we got our approval and not before, we reached out to Serum Institute and got the license, the global license exclusive for the recombinant BCG. We did that because Serum Institute is the world's largest manufacturer of BCG. Most people think it is Merck, and nothing against them, they are fantastic, but Serum is actually the world's largest on those.
In doing that, what it allowed us to do was to be able to say, now we can have, hate to say almost an unlimited supply, but an unlimited supply. We brought that forward to the FDA, and the FDA said, "Great, but we would like to approach this on an expanded access program," which is a blessing and a curse because it takes some work for doctors to be able to do. It is not an authorized product, it is not a trial, but it is somewhere in the middle. We have got a lot of doctors that are doing that, but not every doctor is going to do that. Just this last February at ASCO GU, we also saw the readout, and we were all anxiously waiting for this, which was the Tokyo BCG trial readout, which was Merck's TICE vs the Tokyo-172 BCG strain.
That was a nine-plus-year trial they did. It was 1,000 patients in a head-to-head comparison, and I was hopeful, and I was literally, as we were getting the readout on all those pieces, I was going, "Just please be the same." I actually do not want it to be way stronger or way worse because it is easier to get to an approval if it is almost just a comparable on those pieces, and that is exactly what it was. Since that time, Dr. Soon-Shiong and myself flew to Japan. We negotiated and received the full rights to that, so we have the exclusive rights to the Tokyo BCG. We have had our teams in Japan multiple times because the great news is JBL, or Japan BCG Laboratory, have been making that drug for four decades. It has been approved in Japan forever.
The bad news for us was some of the file or all of the file was in Japanese, and I cannot submit a Japanese file to the U.S. FDA. We paid to have that actually translated, and so the full dossier is now available to us. We have meetings with the FDA where we are working collaboratively with them. I do not have anything to report out in timing yet, but what I can say is that in addition to having that trial, JBL and SWOG, or NIH, have assigned that trial over to ImmunityBio. As we sit here today, ImmunityBio is the IND holder for that 1,000-patient trial, and we have now converted it over. I am looking forward to meeting with the agency to say, "Let's bring something else." Europe has six strains approved.
In the United States, we have got one, and that just is one of those. My real goal is literally to get both approved. If I had to guess, they will probably approve Tokyo BCG faster given the size of that trial, but we are working with them on each of those. It is very important to us, obviously.
Got it. How many patients already on the recombinant BCG?
Yeah, it is well over 1,000, and that is the pieces, and it is complicated because an EAP generally are done in small numbers. When the FDA asked us to do this and said, "Can you just make it available to anybody?" We just smiled and said, "Of course we can." But it is work, and the team at ImmunityBio that is managing that and bringing that out, kudos to them, because they are bringing that available in a much-needed shortage. Actually, the last two conferences, they had physicians, unprompted, were up on stage, and they were talking about it.
The one doctor stops, and he says, "I just want to take a moment and acknowledge ImmunityBio, because without the EAP, we'd actually all be in" I think his exact words were, "Deep doo-doo." Because he says, "We need that here, and so we need to support ImmunityBio through their work with Tokyo as well as recombinant, because we want them both out there." There's a lot of goodwill, but a lot of support from the physicians trying to bring this across the line.
Yeah. We know urology like BCG, and it does save a patient's life. Okay, then the top of the BCG-naïve population, which is, you say it's very much on track to submit a sBLA—
Right.
—by the end of the year. You give us the top line press release, and without any detailed data, people asking, "Okay, why?" Just tell us what's the thinking behind that?
Yeah.
How, when, and how are we going to see the data?
The first thing is I am happy to tell you today that, which we did not previously report out, that trial met its endpoint, but it has a P-value of 0.01.
0.01.
Not only have we met it, but it is very strong statistical significance on those pieces. The reason we have not provided the top line head numbers yet is that we are working with medical congresses to present all of that, and if you give out in a press release, then they do not want to give you the great speaking slot on those. It is a little, I hate to say, it is a little bit of you have to kind of hold some of it back so that you can get something really good. Whether that is at ASCO GU or something sooner, we will work through those, and we are having a lot of those conversations right now. But the more important one on those, and obviously a P-value of 0.01 is just, I was thrilled when I saw that.
You kind of quit looking after that point, is that we are on track to submit the sBLA this year. I personally, when I was in the U.S., was reviewing some of the final modules. In the coming weeks, before 2026 closes out, we will submit that. What Dr. Soon-Shiong and I said earlier in the year, what we reemphasized in that press release, I am here today to tell you that we are in the final stretches of that as well. That is a big game-changer for us.
Got it. We remember your interim data. It is very impressive, right? Everyone going to do the math, 0.01, what that means. Maybe you, can you just say what could be the clinically meaningful CR at six months delta compared to the BCG alone?
Yeah. I actually cannot provide any more on that one because literally we are in conversations with the congresses, and they are asking us to not go deeper on all of those pieces from those. I want to make sure that we are able to obtain those spots.
Yeah.
But we are happy.
Yeah. Maybe just on the control arm, do you see that very consistent with the historical performance, or you cannot say further?
I think if you look at those, there has been multiple trials that have run in BCG, and we are expecting it to come out in that same type of a range. But again, I cannot go into details. As we sit here today, I can just tell you it has met its endpoint. It has got a very strong statistical significance, and we are now just working through where is the best place to present that at.
Got it. Six months CR is the primary endpoint.
It is.
Any other endpoint or follow-up duration you need before you can submit the sBLA?
The primary endpoint is six months CR, and the FDA has told us in writing that it is a registrational intent trial, and that is what they want to see. We will provide duration data that we have on those. We will continue to update it just like we did in the unresponsive setting. We provided to them what we had, provided the KM curves when those were out, and we have updated them since, just as we presented the U.S. one in current label is 47 months and ongoing. Europe is 53 months and ongoing. That is a when you have a drug that lasts as long as this, it is kind of a forever updating piece.
Okay. Got it. All right. Maybe we'll have a couple more minutes, rapid fire. How's the business outside the U.S., and then when are we going to see more meaningful revenue coming from ex-U.S.?
Yeah. ImmunityBio, but everybody woke up one morning and MFN came into the United States, and that changed the way we had to approach Europe. We literally had a very well-thought-out, baked plan that we were ready to launch. I read that and said, "Okay, we got to all stop," because I could literally go there, sell one vial, and cut my U.S. prices by 50%, which would make no sense for everybody. I am proud to say that within weeks or days almost of getting the Because MFN now went from an executive order, again, not related to us, but for everybody, to actually in statute, or maybe not in statute, but in policy.
As soon as that was released, we worked with our fantastic distributors, and we had that out there because we knew what we had to do. We immediately were able to bring that forward in collaboration with them in Germany and Austria, and right away we had immediate sales, and so that's what we just reported out as well. Again, all of this is happening in the now. When we say now, literally in these recent days as we go through those, it's still uncharted water throughout all of those. I'm happy with that there is now something in an HHS policy that we can point to because it removes all of the, "What are we going to do? What are we not going to do?" phase.
I can tell you that I've personally had some of these conversations with HTA authorities and others, and what they've generally said is, "Boy, since MFN has come out, it's like 40 or 50 drugs have either got approved and not launched and/or got withdrawn in Europe." Europe is feeling the impact of that. We have to work through these, and that's what we're doing, and we're having all of these conversations. But when all you had was kind of a shifting line in the sand, you couldn't even start the conversation. Now, as of, I think it was the third week of October, we're able to start those, and right away, we were able to see, because they were as ready as we were, and we were able to launch and go in Germany right away.
Excellent. Last minute, the cash, then how should we think about the pipeline build and the next priority? Particularly, I think one specific is the papillary-only BCG-naïve population.
Yeah. We reported the quarter out at $334 million, and for us, is a great spot again with those pieces. We've been managing cash well on all of those pieces. I think in looking at that, everything that I just told you we did, and we're still in that cash position. I'm feeling really strong about those. As it relates to those, what I'll end you with, because I see the lights flashing, the way to think about ImmunityBio is that we're not an ANKTIVA-only company, we're not a bladder-only company. A lot of people want to pigeonhole that and say that's what it is. That's not. ANKTIVA can be used across multiple franchises. What I always tell folks is think about it, we believe we're going to have a strong bladder franchise because it's now approved in 35 countries.
We're going to have a strong lung franchise. We're approved in two countries. We're running trials to be able to add more in that one. The work we're doing in infectious disease, specifically around sepsis, is incredibly exciting. Cleveland Clinic will be one of the first ones to open that trial. It's authorized by the FDA. It's a blinded randomized control trial, phase II, which, when the FDA first asked for it, I was like, "Jesus, a phase II, a blinded randomized control trial, that's a reach." It's actually a blessing, because we're going to have very objective data.
My, I don't want to say my favorite part, because it's hard to say favorite with sepsis, but maybe the bright side of this is, it's a 28-day readout, because sepsis is such a short disease and you have a short time impact on those, and it's very discreet. It's a yes/no type thing. When we sit down, Dr. Soon-Shiong and myself flew to Cleveland Clinic and we presented it to them, and literally they're like, "We've been treating sepsis wrong. You're suggesting that we treat it as an immune disorder, and we've been treating it as an infection only. It really is the immune system that we have to build through those." Yes, we'll stay with standard of care to treat the infection, but we got to treat the underlying immune system.
They are really excited and collaborating with us to bring this forward. That should be coming live at their sites anytime, as well as others.
Excellent. Thank you, everyone. Thank you, Rich.
Thank you so much.